Helix BioPharma Corp. Strengthens Executive Team with Oncology and Drug Development Experts
TL;DR
Helix BioPharma Corp. strengthens its executive team with top oncology experts to lead groundbreaking development, gaining a competitive edge in cancer therapies.
Helix's new CMO, Dr. Mehrling, will strategically drive the clinical development of Tumor Defence Breaker™ L-DOS47 to enhance immune-oncology therapies for NSCLC.
Helix's commitment to assembling a world-class team aims to bring life-changing therapies to patients faster, improving cancer treatment outcomes and quality of life.
Helix's innovative approach to developing next-gen cancer therapies with bi-specific ADCs and RDCs opens up new horizons in oncology, promising exciting advancements in cancer treatment.
Found this article helpful?
Share it with your network and spread the knowledge!
Helix BioPharma Corp. has announced the addition of three distinguished professionals to its executive team, marking a significant step in its mission to develop groundbreaking cancer treatments. The new appointments include Dr. Thomas Mehrling as Chief Medical Officer, Dr. Jonathan Davis as Director of ADC Discovery, and Dr. Davide Guggi as Chief Technology Officer. These strategic hires underscore Helix's dedication to leveraging top-tier expertise in the fight against hard-to-treat cancers.
Dr. Mehrling, with his extensive background in oncology and drug development, will lead the clinical development strategy for Helix's Tumor Defence Breaker™ L-DOS47, a novel treatment for Non-Small Cell Lung Cancer (NSCLC). His previous roles at major pharmaceutical companies and his success in introducing innovative cancer drugs in Europe highlight the potential impact of his leadership at Helix.
Dr. Davis brings over 15 years of experience in therapeutic antibodies to his role as Director of ADC Discovery. His expertise will be crucial in advancing Helix's portfolio of Antibody-Drug Conjugates (ADCs) targeting Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CECAM6), a promising avenue for treating various solid tumors. Dr. Davis's work is expected to propel the development of next-generation ADCs and radionuclide drug conjugates (RDCs), offering new hope for patients with gastrointestinal and gynecological cancers.
As Chief Technology Officer, Dr. Guggi will oversee the Chemistry, Manufacturing, and Controls (CMC) aspects of Helix's drug development process. His extensive experience in ensuring the scalability and manufacturability of biologics will be instrumental in bringing Helix's innovative therapies to market efficiently and effectively.
The collective expertise of these new team members is a testament to Helix's commitment to transforming oncology treatment paradigms. With a focus on innovation, strategic development, and patient-centric solutions, Helix is poised to make significant strides in the fight against cancer. For more information on Helix BioPharma Corp. and its initiatives, visit https://www.helixbiopharma.com.
Curated from NewMediaWire
